Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Infectious Diseases
Volume 2015, Article ID 504975, 4 pages
http://dx.doi.org/10.1155/2015/504975
Case Report

Treatment of Immunocompromised, Critically Ill Patients with Influenza A H1N1 Infection with a Combination of Oseltamivir, Amantadine, and Zanamivir

1Wilhelmina Children’s Hospital, University Medical Center Utrecht, Lundlaan 6, P.O. Box 85090, Utrecht, Netherlands
2Department of Pharmacy & Pharmacology, Slotervaart Hospital, 1066 EC Amsterdam, Netherlands
3Department of Clinical Pharmacy, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands
4Department of Medical Microbiology, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands
5Department of Hematology, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands
6Department of Virology, Erasmus Medical Center, 3015 CE Rotterdam, Netherlands
7Department of Intensive Care, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands
8Department of Virology, Medical Microbiology, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands

Received 30 May 2015; Revised 21 July 2015; Accepted 28 July 2015

Academic Editor: Ian Barr

Copyright © 2015 Wouter J. Meijer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. W. Thompson, D. K. Shay, E. Weintraub et al., “Mortality associated with influenza and respiratory syncytial virus in the United States,” The Journal of the American Medical Association, vol. 289, no. 2, pp. 179–186, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. K. M. Kunisaki and E. N. Janoff, “Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses,” The Lancet Infectious Diseases, vol. 9, no. 8, pp. 493–504, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. D. M. Weinstock, L. V. Gubareva, and G. Zuccotti, “Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient,” The New England Journal of Medicine, vol. 348, no. 9, pp. 867–868, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. S. B. Graitcer, L. Gubareva, L. Kamimoto et al., “Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States,” Emerging Infectious Diseases, vol. 17, no. 2, pp. 255–257, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. 2015, http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
  6. C. Renaud, A. A. Boudreault, J. Kuypers et al., “H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients,” Emerging Infectious Diseases, vol. 17, no. 4, pp. 653–660, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Lackenby, O. Hungnes, S. G. Dudman et al., “Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe,” Euro Surveillance, vol. 13, no. 5, article 2, 2008. View at Google Scholar · View at Scopus
  8. G. He, J. Massarella, and P. Ward, “Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802,” Clinical Pharmacokinetics, vol. 37, no. 6, pp. 471–484, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Seo, J. A. Englund, J. T. Nguyen et al., “Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics,” Antiviral Therapy, vol. 18, no. 3, pp. 377–386, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. W.-Y. Kim, G. Y. Suh, J. W. Huh et al., “Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 12, pp. 5703–5709, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. J. T. Nguyen, D. F. Smee, D. L. Barnard et al., “Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza a viruses,” PLoS ONE, vol. 7, no. 1, Article ID e31006, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. A. S. Perelson, L. Rong, and F. G. Hayden, “Combination antiviral therapy for influenza: predictions from modeling of human infections,” The Journal of Infectious Diseases, vol. 205, no. 11, pp. 1642–1645, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Petersen, D. B. Keld, S. Ellermann-Eriksen et al., “Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v,” Scandinavian Journal of Infectious Diseases, vol. 43, no. 6-7, pp. 495–503, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. P. L. A. Fraaij, E. van der Vries, M. F. C. Beersma et al., “Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection,” Journal of Infectious Diseases, vol. 204, no. 5, pp. 777–782, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Dunning, J. K. Baillie, B. Cao, and F. G. Hayden, “Antiviral combinations for severe influenza,” The Lancet Infectious Diseases, vol. 14, no. 12, pp. 1259–1270, 2014. View at Publisher · View at Google Scholar · View at Scopus